[Oral opioids in patients with non-malignant pain.].

Der Schmerz
M ZenzA Willweber-Strumpf

Abstract

Opioids are given for acute intra- and postope-rative pain relief or for chronic cancer pain. In the literature there are only rare and contradictory reports on the oral administration of opioids for chronic non-malignant pain. However, there is no reason to withhold strong analgesics for patients with severe pain. When all other thrapeutic measures fail to control pain, patients with non-malignant pain can also be treated by opioids. We report 70 patients with severe pain who were given opioids as the ultima ratio in pain therapy: 50 received buprenorphine sublingual tablets, 13 received morphine sustained release tablets and the remaining 7 were treated with other opioids. The mean daily dose was 1.45 mg buprenorphine or 87.6 mg morphine. The dosage increased in 12 of the 50 patients treated with buprenorphine while 5 of the 13 morphine patients needed increasing dosage. The other patients had a constant dosage after the initial period of dose-finding. In more than 50% the pain could be effectively controlled by oral opioids. The general performance status (Karnofsky) increased from 63.6% to 74.1%. The typical side effects were constipation and nausea. Prophylaxis of constipation is most important during opioid therapy. No ca...Continue Reading

References

Jun 1, 1976·Pain·J Scott, E C Huskisson
Mar 22, 1985·Deutsche medizinische Wochenschrift·M ZenzW Klauke
Feb 27, 1988·British Medical Journal·E K RodrigoP Williams
Jan 13, 1989·Deutsche medizinische Wochenschrift·M ZenzB Steffmann
Dec 1, 1988·Pain·H L Fields
Mar 1, 1988·Journal of Neurology·R K PortenoyD Thorton
Apr 1, 1982·Pain·Judith A TurnerBrian L Ready
Aug 27, 1983·Lancet·G W HanksE Weeks
Jul 1, 1984·Drugs·G K Gourlay, M J Cousins
Jan 1, 1984·Social Science & Medicine·R D FranceF J Keefe
Apr 6, 1984·JAMA : the Journal of the American Medical Association·B KvinesdalL F Gram
Jan 1, 1984·Medical Education·M W Ross
Jan 1, 1983·Postgraduate Medicine·J Tennant FS, G F Uelmen
Jan 10, 1980·The New England Journal of Medicine·J Porter, H Jick
Mar 1, 1988·Der Schmerz·E Hackenthal
Mar 1, 1988·Der Schmerz·M Mumenthaler
Mar 1, 1988·Der Schmerz·H A Baar
Mar 1, 1988·Der Schmerz·R Wörz
Sep 1, 1988·Der Schmerz·W Keup
Mar 1, 1989·Der Schmerz·R Wörz, J Berlin

❮ Previous
Next ❯

Citations

Mar 1, 1993·Der Schmerz·R Wörz
Sep 1, 1990·Der Schmerz·M Zimmermann
Sep 1, 1992·Der Schmerz·J SorgeE Hackenthal
Jun 1, 1991·Der Schmerz·B Kossmann, U Thoden
Jun 1, 1991·Der Schmerz·D Zech
Jun 1, 1991·Der Schmerz·C MaierC Maier
Jun 1, 1991·Der Schmerz·M ZenzA Willweber-Strumpf
Mar 1, 1992·Der Schmerz·M Zimmermann
Mar 1, 1991·Der Schmerz·M Zenz
Jan 1, 1995·Der Schmerz·N I ChernyM Zenz
Jun 24, 2011·Der Schmerz·M Zenz, R Rissing-van Saan
May 28, 1998·Journal of Pain and Symptom Management·B DonnerR Dertwinkel
Sep 1, 1996·Journal of Neurosurgery·M Winkelmüller, W Winkelmüller
Sep 4, 2020·Der Schmerz·Michael Zenz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.